

Resource Summary Report

Generated by [NIF](#) on Sep 4, 2026

Drug-Interactions

RRID:SCR_002336

Type: Tool

Proper Citation

Drug-Interactions (RRID:SCR_002336)

Resource Information

URL: <http://medicine.iupui.edu/clinpharm/ddis/>

Proper Citation: Drug-Interactions (RRID:SCR_002336)

Description: Table designed as a hypothesis testing, teaching and reference tool for physicians and researchers interested in drug interactions that are the result of competition for, or effects on the human cytochrome P450 system. The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. A drug appears in a column if there is published evidence that it is metabolized, at least in part, via that isoform. It does not necessarily follow that the isoform is the principal metabolic pathway in vivo, or that alterations in the rate of the metabolic reaction catalyzed by that isoform will have large effects on the pharmacokinetics of the drug., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: Drug Interactions

Synonyms: Cytochrome P450 Drug Interaction Table, Cytochrome P450 Drug Interactions, P450 Drug Interactions

Resource Type: data or information resource, data set

Keywords: drug, cytochrome p450, cytochrome, interaction, isoform, metabolic, p450, pathway, pharmacokinetic, physician, substrate, clincial, inhibitor, inducer, drug interaction, genetics

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Drug-Interactions

Resource ID: SCR_002336

Alternate IDs: nif-0000-21132

Alternate URLs: <http://drug-interactions.com>

Record Creation Time: 20220129T080212+0000

Record Last Update: 20260904T000606+0000

Ratings and Alerts

No rating or validation information has been found for Drug-Interactions.

No alerts have been found for Drug-Interactions.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

St??hlinger MC, et al. (2020) Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wiener klinische Wochenschrift, 132(3-4), 97.

Nahid P, et al. (2019) Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American journal of respiratory and critical care medicine, 200(10), e93.

Yan MM, et al. (2018) Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE open medicine, 6, 2050312118798278.

Yi JM, et al. (2015) Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC complementary and alternative medicine, 15, 441.

Weitzman SP, et al. (2015) The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer management and research, 7, 265.